Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
13.85
-0.20
(-1.42%)
At close: February 28 at 4:00:02 PM EST
13.85
-0.00
(-0.00%)
After hours: February 28 at 6:19:11 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 8 | 11 | 11 |
| Avg. Estimate | 0.37 | 0.19 | 0.51 | 1.29 |
| Low Estimate | 0.31 | 0.13 | 0.46 | 1.09 |
| High Estimate | 0.4 | 0.28 | 0.55 | 1.5 |
| Year Ago EPS | 0.19 | -0.04 | 1.4 | 0.51 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 8 | 11 | 11 |
| Avg. Estimate | 703.22M | 661.39M | 2.7B | 2.74B |
| Low Estimate | 700.3M | 642.59M | 2.7B | 2.7B |
| High Estimate | 713.17M | 675M | 2.71B | 2.84B |
| Year Ago Sales | 775.4M | 662.1M | 3.11B | 2.7B |
| Sales Growth (year/est) | -9.31% | -0.11% | -13.07% | 1.36% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.23 | 0 | 0.06 | 0.25 |
| EPS Actual | 0.19 | -0.04 | -0.03 | 0.23 |
| Difference | -0.04 | -0.04 | -0.09 | -0.02 |
| Surprise % | -17.93% | -1,382.05% | -146.90% | -8.33% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.37 | 0.19 | 0.51 | 1.29 |
| 7 Days Ago | 0.37 | 0.2 | 0.51 | 1.29 |
| 30 Days Ago | 0.37 | 0.2 | 0.52 | 1.31 |
| 60 Days Ago | 0.37 | 0.22 | 0.53 | 1.32 |
| 90 Days Ago | 0.37 | 0.22 | 0.53 | 1.27 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | 1 | 1 | 1 | 2 |
| Down Last 30 Days | 2 | 1 | 2 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| FTRE | 92.24% | 583.98% | -63.36% | 152.22% |
| S&P 500 | 16.04% | 7.30% | 10.62% | 14.20% |
Upgrades & Downgrades
| Downgrade | Citigroup: Buy to Neutral | 12/11/2024 |
| Downgrade | Baird: Outperform to Neutral | 12/6/2024 |
| Maintains | Baird: Outperform to Outperform | 11/25/2024 |
| Maintains | TD Cowen: Hold to Hold | 11/11/2024 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 11/11/2024 |
| Maintains | Baird: Outperform to Outperform | 11/11/2024 |
Related Tickers
SNDX Syndax Pharmaceuticals, Inc.
15.64
+2.36%
OCUL Ocular Therapeutix, Inc.
7.14
+2.88%
ZLAB Zai Lab Limited
34.64
+0.76%
ARQT Arcutis Biotherapeutics, Inc.
13.69
+6.95%
APLS Apellis Pharmaceuticals, Inc.
25.15
-3.27%
XENE Xenon Pharmaceuticals Inc.
37.02
-3.37%
MRVI Maravai LifeSciences Holdings, Inc.
3.2200
+5.57%
BEIGF BeiGene, Ltd.
15.14
+5.14%
MDXG MiMedx Group, Inc.
8.41
+3.26%
ONC BeiGene, Ltd.
271.80
-2.36%